Aegerion Announces Phase III 56-Week Data. YM BioSciences Announces Orphan Drug Designation. Print E-mail
By BioMedReports.com Staff   
Tuesday, 31 May 2011 19:54
Aegerion Announces Phase III 56-Week Data. YM BioSciences Announces Orphan Drug Designation.

Below is a look at some of the headlines for companies that made news in the healthcare sector on May 31, 2011.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) announced a pivotal Phase III clinical trial for its lomitapide, results in the 56-week data were consistent with the data seen in the same study at 26 weeks. The FDA has designated Lomitapide as an orphan drug for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

The single-arm, open label trial is designed to evaluate the efficacy and long-term safety. With data showing lomitapide reduced cholesterol substantially in patients with HoFH.


YM BioSciences Inc. (AMEX:YMI) announced its JAK1/JAK2 inhibitor, CYT387 has received positive opinions from the Committee for Orphan Medicinal Products of the European Commission to grant Orphan Medicinal Product Designation, for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

Myelofibrosis is a chronic debilitating unmet medical need in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.


Also Tuesday:


Amicus Therapeutics (Nasdaq:FOLD) today announced that Matthew R. Patterson, President and Acting Chief Executive Officer, will present a corporate overview at the Jefferies 2011 Global Healthcare Conference in New York, NY on Tuesday, June 7 at 12:15 p.m. ET.

Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN)
will be presenting at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 12:20 p.m. ET / 9:20 a.m. PT in Palos Verdes, California and at the Jeffries Global Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ET / 7:00 a.m. PT in New York.

AstraZeneca (NYSE:AZN) and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs).

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced that company management will present an overview of the company at the Jefferies 2011 Global Healthcare Conference in New York, NY.

Bacterin International Holdings, Inc. (NYSE Amex:BONE)
, a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that it has entered into an equity purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago based asset management firm.

Caliper Life Sciences, Inc. (NASDAQ:CALP) today announced that its presentation at the Jefferies 2011 Global Life Sciences Conference, will be webcast on Wednesday, June 8 at 11:00 a.m. EDT.

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that results from an economic analysis carried out by the UK NHS National Innovation Centre identified the Celution® System for breast reconstruction as an innovative technology that is bringing benefits to National Health Service (NHS) hospitals and breast cancer patients.

TheDirectory.com, Inc. (PINKSHEETS: EYSM), an emerging leader in the Local business search market , today confirmed that it has completed its seventh month in a row of Top-Line revenue growth and finished the best quarter it has ever had.

D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that, due to its decision to focus on the commercialization of its current and future products, it is considering selling its holdings in its publicly held subsidiary, NextGen Biomed Ltd. ("NextGen").

First China Pharmaceutical Group, Inc. (OTCBB: FCPG) ("First China" or the "Company") wishes to advise that both parties have agreed to proceed with financial and legal due diligence as part the next step in the proposed acquisition of 100% of the interests of Shenzhen Ming He Tang Pharmaceutical Co., Ltd. ("Min He Tang") of Shenzhen City, Guangdong Province.

GeckoSystems Intl. Corp, (PINKSHEETS: GOSY), a dynamic leader in the emerging mobile robotics industry revolutionizing their development and usage with "Mobile Robot Solutions for Safety, Security and Service™," -- announced today they have improved one of their mobile robot solutions, the GeckoMotorController™ 7.2, due to better testing at their new R&D facility.

Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that it has entered into a binding letter agreement to license its RapidMist™ buccal drug delivery technologies to Amarantus BioSciences, Inc. (www.amarantus.com), a California-based biotechnology company, for use with its proprietary MANF proteins in exchange for a non-refundable license fee of $10 million.  

Health Enhancement Products, Inc. (OTCBB: HEPI) has executed the first phase of a multi-phase R&D contract with Columbus, Ohio-based Battelle to refine, analyze and potentially synthesize the active molecules derived from its proprietary algal extracts.

InspireMD, Inc. (OTC BB: NSPR), the developer of the MGuard™ mesh protective stent system, today announced another positive study, reinforcing MGuard's position in the cardiology market.

Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 10:30 a.m. Eastern Time in New York City.

Life Technologies Corporation (NASDAQ:LIFE) today announced it is now shipping the Ion Total RNA-Seq Kit for the Ion Personal Genome Machine (PGM™) sequencer, a solution that provides a fast, affordable, easy-to-use alternative to microarrays for transcript expression analysis.

Luminex Corporation (Nasdaq:LMNX) today announced that management will present at the Jefferies 2011 Global Healthcare Conference to be held June 6-9 in New York.

Medizone International, Inc. (OTCQB: MZEI) (OTCBB: MZEI) will hold a teleconference on Wednesday, June 8, 2011 at 3:00 p.m., PDT, to discuss company developments.

MultiCell Technologies, Inc. (OTC Bulletin Board: MCET)
is pleased to announce the issuance of U.S. patent 7,935,528 by the United States Patent and Trademark Office (USPTO) relating to the isolation and use of human liver stem cells to treat liver disease.

Neurocrine Biosciences, Inc. (Nasdaq:NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2011 Global Healthcare Conference in New York.

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company plans to present at two investor conferences in June.

PROLOR Biotech, Inc., (NYSE Amex:PBTH)
, a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Jefferies 2011 Global Healthcare Conference on June 6, 2011 at 9:30 AM ET.

Regal One Corporation (OTCBB:RONE), an emerging business development corporation that is 100% focused on incubating and bringing public high quality companies, today announced it will distribute a special dividend of 300,000 shares of Rampart Detection Systems Ltd Common stock.

Sinovac Biotech Ltd. (NASDAQ:SVA)
, a leading provider of biopharmaceutical products in China, announced today the appointment of Mr. Kenneth Lee as a director to the Board of the Company effective on May 31, 2011 to replace Mr. Xianping Wang who resigned from the Board due to personal reasons.

Syneron Medical Ltd. (NASDAQ:ELOS) held a media panel on the specific challenges of Asian skin and ways to successfully satisfy the increasing demands of Asian consumers regarding skin tone and appearance.

Techs Loanstar, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) today announced additional details regarding its previously announced pending acquisition target, Q'uture, Inc.

Unilife Corporation (NASDAQ:UNIS; ASX: UNS) today announced that it will be presenting at the 2011 Jefferies Global Healthcare Conference in New York City.

Versus Technology, Inc.  (PINKSHEETS: VSTI), announced revenues of $1,311,000 for its second fiscal quarter ended April 30, 2011, a 47.8% decrease compared to revenues of $2,513,000 for the same quarter of the prior year.

YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM)
, today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO).

World Health Energy Holdings, Inc. (PINKSHEETS: WHEN) (OTCQB: WHEN), a public holding company focused on developing algae farms for the production of biodiesel and fish food for commercial fish farms, announced today that the company's wholly-owned subsidiary, GNE-India, has reached a Memorandum of Understanding with David Lobo from Deejay Coconut Farm PVT via a joint venture to initially build a 2.5-acre commercial algae farm in Bangalore, India.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter